In 2018, after nearly two decades working in Big Pharma, chemist Tim Cernak was ready to put his skills to a new use.  For Merck, he’d developed precision therapies for cancer, HIV, and diabetes that could target disease while minimizing harm to healthy cells. But as a lifel